A study of population pharmacokinetics of Ibrutinib in healthy adults, and explores potential patient characteristics associated with Ibrutinib pharmacokinetics
Latest Information Update: 25 Mar 2021
At a glance
- Drugs Ibrutinib (Primary)
- Indications Acute myeloid leukaemia; B-cell lymphoma; Cancer; Chronic lymphocytic leukaemia; CNS cancer; Colorectal cancer; Diffuse large B cell lymphoma; Follicular lymphoma; Gastrointestinal cancer; Graft-versus-host disease; Hairy cell leukaemia; Lymphoma; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Multiple myeloma; Myelodysplastic syndromes; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Pancreatic cancer; Precursor cell lymphoblastic leukaemia-lymphoma; Renal cell carcinoma; SARS-CoV-2 acute respiratory disease; Solid tumours; Squamous cell cancer; T-cell prolymphocytic leukaemia; Urogenital cancer; Waldenstrom's macroglobulinaemia
- Focus Pharmacokinetics
- 25 Mar 2021 New trial record
- 19 Mar 2021 Results published in the European Journal of Drug Metabolism and Pharmacokinetics